HUP0303194A2 - DKK-1 és antagonistái alkalmazásai - Google Patents
DKK-1 és antagonistái alkalmazásaiInfo
- Publication number
- HUP0303194A2 HUP0303194A2 HU0303194A HUP0303194A HUP0303194A2 HU P0303194 A2 HUP0303194 A2 HU P0303194A2 HU 0303194 A HU0303194 A HU 0303194A HU P0303194 A HUP0303194 A HU P0303194A HU P0303194 A2 HUP0303194 A2 HU P0303194A2
- Authority
- HU
- Hungary
- Prior art keywords
- dkk
- treatment
- antagonists
- hypoinsulinemia
- obesity
- Prior art date
Links
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 title abstract 7
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 title abstract 7
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 2
- 206010070070 Hypoinsulinaemia Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 2
- 201000008980 hyperinsulinism Diseases 0.000 abstract 2
- 230000035860 hypoinsulinemia Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A találmány tárgya Dickkopf-1 (Dkk-1) fehérjék antagonistáinakalkalmazása inzulinrezisztenziával - például nem inzulinfüggő diabetesmellitus (NIDDM), hipoinsulinaemia - és izomsorvadással, traumávalvagy degenerációval járó elváltozások kezelésére szolgáló gyógyszerek,készítmények, illetve készletek előállítására. Előnyös, ha azantagonisták a Dkk-1 hatásainak gátlására alkalmas, Dkk-1 elleniantitesteket tartalmaznak. Továbbá, a találmány tárgya készletekelhízottság vagy hiperinzulinémia kezelésére emlősben, továbbá Dkk-1alkalmazása emlősben ilyen rendellenességek kezelésére szolgálókészítmények előállítására. Továbbá, a találmány tárgyát képezikinzulinnal szembeni rezisztencia, hiper- vagy hipoinzulinémia,elhízottság és ezekkel rokon elváltozások diagnosztizálására szolgálóeljárások Dkk-l-et, és dkk-1 nukleinsavat túlexpresszáló, embertőlkülönböző; transzgénikus állatok alkalmazásával. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26943501P | 2001-02-16 | 2001-02-16 | |
| PCT/US2002/004573 WO2002066509A2 (en) | 2001-02-16 | 2002-02-15 | Treatment involving dkk-1 or antagonists thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0303194A2 true HUP0303194A2 (hu) | 2003-12-29 |
Family
ID=23027234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303194A HUP0303194A2 (hu) | 2001-02-16 | 2002-02-15 | DKK-1 és antagonistái alkalmazásai |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030165501A1 (hu) |
| EP (1) | EP1360199A2 (hu) |
| JP (1) | JP2005509402A (hu) |
| KR (1) | KR20030087001A (hu) |
| AU (1) | AU2002306505B2 (hu) |
| CA (1) | CA2438245A1 (hu) |
| HU (1) | HUP0303194A2 (hu) |
| IL (1) | IL157328A0 (hu) |
| MX (1) | MXPA03007327A (hu) |
| PL (1) | PL374006A1 (hu) |
| WO (1) | WO2002066509A2 (hu) |
| ZA (1) | ZA200306232B (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| CA2446582A1 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
| US8858434B2 (en) | 2004-07-13 | 2014-10-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
| ES2342152T3 (es) | 2002-04-17 | 2010-07-02 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Metodo para identificacion de un compuesto para modulacion de la cascada de señales wnt. |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US20050169995A1 (en) * | 2003-10-03 | 2005-08-04 | Kuo Calvin J. | Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway |
| EP2093298A3 (en) | 2003-10-10 | 2009-09-23 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins) |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US7867699B2 (en) | 2004-03-23 | 2011-01-11 | Wyeth | Method of synthesizing and purifying Dkk proteins and Dkk proteins obtained thereby |
| US7709611B2 (en) * | 2004-08-04 | 2010-05-04 | Amgen Inc. | Antibodies to Dkk-1 |
| WO2006015497A1 (en) * | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
| SG170642A1 (en) * | 2004-11-03 | 2011-05-30 | Arena Pharm Inc | Gpr41 and modulators thereof for the treatment of insulin-related disorders |
| WO2006089114A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating an anthrax toxin mediated condition |
| AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| KR20070113499A (ko) * | 2006-05-24 | 2007-11-29 | 연세대학교 산학협력단 | Ｄｋｋ1을 포함하는 혈관신생을 억제시키는 방법 |
| AU2008214344B2 (en) * | 2007-02-08 | 2012-06-07 | Merck Sharp & Dohme Corp. | Antibodies specific for Dkk-1 |
| EP2098244A1 (en) | 2008-03-04 | 2009-09-09 | Medizinische Hochschule Hannover | Pharmaceutical composition for the treatment of myocardial infarction |
| AU2010245833B2 (en) * | 2009-05-07 | 2014-03-27 | Novartis Ag | Compositions and methods of use for binding molecules to Dickkopf-1 or Dickkopf-4 or both |
| RU2548817C2 (ru) * | 2009-05-12 | 2015-04-20 | Пфайзер Инк. | БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ |
| CN106191215B (zh) | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
| CN112180094A (zh) * | 2019-07-04 | 2021-01-05 | 上海东慈生物科技有限公司 | Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187991B1 (en) * | 1995-05-23 | 2001-02-13 | Pfizer Inc | Transgenic animal models for type II diabetes mellitus |
| WO2000052047A2 (en) * | 1999-03-05 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
-
2002
- 2002-02-15 KR KR10-2003-7010720A patent/KR20030087001A/ko not_active Application Discontinuation
- 2002-02-15 HU HU0303194A patent/HUP0303194A2/hu unknown
- 2002-02-15 CA CA002438245A patent/CA2438245A1/en not_active Abandoned
- 2002-02-15 JP JP2002566222A patent/JP2005509402A/ja not_active Withdrawn
- 2002-02-15 MX MXPA03007327A patent/MXPA03007327A/es not_active Application Discontinuation
- 2002-02-15 PL PL02374006A patent/PL374006A1/xx unknown
- 2002-02-15 US US10/077,065 patent/US20030165501A1/en not_active Abandoned
- 2002-02-15 EP EP02742479A patent/EP1360199A2/en not_active Withdrawn
- 2002-02-15 WO PCT/US2002/004573 patent/WO2002066509A2/en not_active Application Discontinuation
- 2002-02-15 AU AU2002306505A patent/AU2002306505B2/en not_active Expired - Fee Related
- 2002-02-15 IL IL15732802A patent/IL157328A0/xx unknown
-
2003
- 2003-08-12 ZA ZA200306232A patent/ZA200306232B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002306505B2 (en) | 2007-02-15 |
| ZA200306232B (en) | 2004-11-17 |
| WO2002066509A3 (en) | 2003-01-23 |
| MXPA03007327A (es) | 2005-02-14 |
| CA2438245A1 (en) | 2002-08-29 |
| KR20030087001A (ko) | 2003-11-12 |
| PL374006A1 (en) | 2005-09-19 |
| EP1360199A2 (en) | 2003-11-12 |
| WO2002066509A2 (en) | 2002-08-29 |
| US20030165501A1 (en) | 2003-09-04 |
| JP2005509402A (ja) | 2005-04-14 |
| IL157328A0 (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303194A2 (hu) | DKK-1 és antagonistái alkalmazásai | |
| Lockhart et al. | GDF15: a hormone conveying somatic distress to the brain | |
| Thisse et al. | Spatial and temporal expression patterns of selenoprotein genes during embryogenesis in zebrafish | |
| WO2008060364A3 (en) | Humani zed antibody against amyloid beta | |
| PH12011502389A1 (en) | Monoclonal antibody | |
| Jeong et al. | Allergenicity of recombinant Bla g 7, German cockroach tropomyosin | |
| WO2005019258A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| WO2004024068A3 (en) | Novel composition and methods for the treatment of immune related diseases | |
| WO2004047728A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| BRPI0519775A2 (pt) | proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica | |
| EP2322201A3 (en) | Compositions and methods for the treatment of immune related diseases | |
| JP2004532817A5 (hu) | ||
| WO2004043361A3 (en) | Compositions and methods for the treatment of natural killer cell related diseases | |
| WO2004024090A3 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| Shanmugarajan et al. | Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling | |
| WO2005040418A3 (en) | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt | |
| WO2002056893A8 (en) | Novel receptors for $i(helicobacter pylori) and use thereof | |
| CN105555297A (zh) | Wnt组合物及纯化方法 | |
| WO2004024072A3 (en) | Novel compositions and methods for the treatment of immune related diseases | |
| WO2004081199A3 (en) | Novel compositions and methods for the treatment of immune related disease | |
| WO2009095452A8 (en) | Crystal structure of the atpase domain of proteins of the hsp70 family | |
| Kim et al. | Multiple ligand interaction of α-synuclein produced various forms of protein aggregates in the presence of Aβ25-35, copper, and eosin | |
| WO2004022756A3 (en) | Protein kinases |